ASCO-GI 2024 updates with Dr. Saab from Mayo Clinic

In this ASCO-GI research special, Dr. Bekaii-Saab of Mayo Clinic provides an insightful and comprehensive roundup of the most groundbreaking studies unveiled at the ASCO GI 2024 meeting.
He joins me on Healthcare unfiltered to Delve into the realm of hepato-cellular carcinoma, he dissects the pivotal previously-reported data from IMbrave050 and ASCO GI findings from EMERALD-1. Then, he sheds light on developments in colorectal cancer, exploring the impact of KEYNOTE-177 and CheckMate 8HW. Moreover, Dr. Bekaii-Saab explores the latest advancements in minimal residual disease assessment with a focus on studies like BESPOKE and GALAXY, as well as the prognostic value of ctDNA assessment showcased in COBRA
A must listen podcast for everyone interested in GI cancers. Don't forget to check out my website and also my book "Toxic Exposure" available everywhere.